<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="203744">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436982</url>
  </required_header>
  <id_info>
    <org_study_id>K-S-015 Triathlon RSA_1</org_study_id>
    <secondary_id>K-S-015_1</secondary_id>
    <nct_id>NCT00436982</nct_id>
  </id_info>
  <brief_title>Evaluation of Triathlon - a New Total Knee Prosthesis System - Triathlon vs. Duracon</brief_title>
  <official_title>Evaluation of Triathlon - a New Total Knee Prosthesis System. Prospective, Comparative, Randomised, Roentgen Stereophotogrammetric Analysis (RSA) Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker European Operations BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker European Operations BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to investigate the Clinical, Radiographic, Roentgen Stereophotogrammetric
      behaviour and patient outcome when using the Triathlon total knee prosthesis in a
      prospective randomized clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The evaluation is carried out by a prospective randomised RSA-study with Triathlon cemented
      knee prosthesis versus Duracon cemented knee prosthesis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Roentgen Stereophotogrammetric Analysis (RSA)</measure>
    <time_frame>2 years</time_frame>
    <description>To compare the maximum total point motion of the Triathlon and Duracon tibial components after two years assessed by means of RSA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Objective is to Investigate the Clinical, Radiographic, Roentgen Stereophotogrammetric Behaviour and Patient Outcome in a Prospective Randomized Clinical Trial.</measure>
    <time_frame>3 months, 1, 2, 5, 7 and 10 years</time_frame>
    <description>Plain radiographs for disease class. Clinical assessment AKSS and KOOS score. Post operative FU all plain radiographs for assessment of the component position.
Yearly radiographic FU to assess wear, radiolucent zones and stress resorption and patella sky view projection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <arm_group>
    <arm_group_label>Cemented Triathlon total knee system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Triathlon total knee system is the successor of the Duracon total knee system and was observed in a prospective randomised, parallel, double-blind study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cemented Duracon total knee system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Duracon total knee system is the predecessor of the Triathlon total knee system and was observed in a prospective randomised, parallel, double-blind study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cemented Triathlon total knee system</intervention_name>
    <description>Orthopaedic implant</description>
    <arm_group_label>Cemented Triathlon total knee system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Duracon total knee system</intervention_name>
    <description>Orthopaedic implant</description>
    <arm_group_label>Cemented Duracon total knee system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients suffering exclusively from osteo arthritis (OA), Stage II-V [Ahlbäck, 1968]
             will be operated.

          2. Patients requiring knee prosthesis, suitable for the use of Duracon and Triathlon
             knee system

          3. Patients who understand the conditions of the study and are willing and able to
             comply with the post-operative scheduled clinical and radiographical evaluations and
             the prescribed rehabilitation.

          4. Patients who signed the Ethics Committee approved Informed Consent Form prior to
             surgery.

        Exclusion Criteria:

          1. Previous major knee surgery

          2. Other significant disabling problems from the muscular-skeletal system than in the
             knees

          3. Obese patients where obesity is severe enough to affect subject's ability to perform
             activities of daily living (body mass index, kg/m2: BMI above 35).

          4. Patients with active or suspected infection.

          5. Patients with malignancy - active malignancy.

          6. Patients with severe osteoporosis, Paget's disease, renal osteodystrophy.

          7. Patients immunologically suppressed, or receiving steroids in excess of physiologic
             dose requirements.

          8. The patient has a neuromuscular or neurosensory deficit which would limit the ability
             to assess the performance of the device or the patient has a neurological deficit
             which interferes with the patient's ability to limit weight bearing or places an
             extreme load on the implant during the healing period.

          9. Female patients planning a pregnancy during the course of the study.

         10. Patients with systemic or metabolic disorders leading to progressive bone
             deterioration.

         11. Patients, who as judged by the surgeon, are mentally incompetent or are unlikely to
             be compliant with the prescribed post-operative routine and follow-up evaluation
             schedule.

         12. Patients with other severe concurrent joint involvements, which can affect their
             outcome.

         13. Patients with other concurrent illnesses, which are likely to affect their outcome
             such as sickle cell anaemia, systemic lupus erythematosus or renal disease requiring
             dialysis.

         14. Patients under the protection of law (e.g. guardianship).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sören Toksvig-Larsen, ass. prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of ortopaedics, Hässleholm Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hässleholm Hospital</name>
      <address>
        <city>Hässleholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Molt M, Ljung P, Toksvig-Larsen S. Does a new knee design perform as well as the design it replaces? Bone Joint Res. 2012 Dec 1;1(12):315-23. doi: 10.1302/2046-3758.112.2000064.</citation>
    <PMID>23610663</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>February 16, 2007</firstreceived_date>
  <firstreceived_results_date>September 29, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was from February to November 2006. In a single centre patients were prospectively randomised to receive either a cemented Triathlon total knee system or a Duracon total knee system. Randomisation with envelopes, 30 patients in each group.</recruitment_details>
      <pre_assignment_details>Reason for exclusion from trial prior to assignment to the two groups:
Not meeting inclusion criteria (n = 34)
Declined to participate (n = 24)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cemented Triathlon Total Knee System</title>
          <description>30 patients were randomized into the Triathlon total knee system arm. TheTriathlon total knee system is the successor of the Duracon total knee system and was observed in a prospective randomised, parallel, double-blind study.
Cemented Triathlon total knee system: Orthopaedic implant</description>
        </group>
        <group group_id="P2">
          <title>Duracon Total Knee System</title>
          <description>30 patients were randomized into the Duracon total knee system arm. The Duracon total knee system is the predecessor of the Triathlon total knee system and was observed in a prospective randomised, parallel, double-blind study.
Duracon total knee system: Orthopaedic implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive allocated intervention</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>With an alpha of 0.05 and a beta of 0.20 the required sample size in each group is 25 patients to detect a difference of 0.3 mm. Patients with inadequate marking will be excluded from the study. Taking the latter into account and to compensate for possible lost to follow up, 30 patients will be recruited per study group.</population>
      <group_list>
        <group group_id="B1">
          <title>Triathlon</title>
          <description>30 patients randomized into the Triathlon arm</description>
        </group>
        <group group_id="B2">
          <title>Duracon</title>
          <description>30 patients randomized into the Duracon arm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="47" upper_limit="86"/>
                    <measurement group_id="B2" value="66" lower_limit="47" upper_limit="84"/>
                    <measurement group_id="B3" value="68" lower_limit="47" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Roentgen Stereophotogrammetric Analysis (RSA)</title>
        <description>To compare the maximum total point motion of the Triathlon and Duracon tibial components after two years assessed by means of RSA.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triathlon</title>
            <description>30 patients randomized into the Triathlon arm</description>
          </group>
          <group group_id="O2">
            <title>Duracon</title>
            <description>30 patients randomized into the Duracon arm</description>
          </group>
        </group_list>
        <measure>
          <title>Roentgen Stereophotogrammetric Analysis (RSA)</title>
          <description>To compare the maximum total point motion of the Triathlon and Duracon tibial components after two years assessed by means of RSA.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.26"/>
                    <measurement group_id="O2" value="0.76" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Objective is to Investigate the Clinical, Radiographic, Roentgen Stereophotogrammetric Behaviour and Patient Outcome in a Prospective Randomized Clinical Trial.</title>
        <description>Plain radiographs for disease class. Clinical assessment AKSS and KOOS score. Post operative FU all plain radiographs for assessment of the component position.
Yearly radiographic FU to assess wear, radiolucent zones and stress resorption and patella sky view projection.</description>
        <time_frame>3 months, 1, 2, 5, 7 and 10 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During entire 2 years follow-up of all patients</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Triathlon</title>
          <description>30 patients randomized into the Triathlon arm</description>
        </group>
        <group group_id="E2">
          <title>Duracon</title>
          <description>30 patients randomized into the Duracon arm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep-vein Thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fracture proximal tibia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Patella misalignment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sören Toksvig-Larsen, M.D., Ph.D., Ass. Professor</name_or_title>
      <organization>Department of Orthopedics Hässleholm Hospital Organization</organization>
      <phone>+46 (0) 451 29 64 70</phone>
      <email>ortopeden.hlm@skane.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
